Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
JPMorgan Removes Akero Therapeutics (AKRO) from Analyst Focus List and Catalyst Watch, PT $62
October 10, 2023 12:35 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO).
The analyst comments "In our view, the totality of the SYMMETRY dataset continues to support EFX having a differentiated impact on histology across the spectrum of... More
Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'
October 10, 2023 8:21 AM EDTCanaccord Genuity analyst Edward Nash reiterated a Buy rating and $59.00 price target on Akero Therapeutics (NASDAQ: AKRO)
The analyst comments "Akero Therapeutics reports 36-week analysis of SYMMETRY, a 96-week Phase IIb study evaluating the efficacy and safety of its lead product candidate efruxifermin... More
Cantor Fitzgerald on Akero Therapeutics (AKRO), 'we expect the stock to trade down'
October 10, 2023 7:55 AM EDTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $69.00 price target on Akero Therapeutics (NASDAQ: AKRO)
The analyst comments "EFX efficacy meets our mixed scenario, and we expect the stock to trade down (premarket stock is trading down 50%+, which seems an... More
